Search Result

Results for "

ATR inhibitor

" in MedChemExpress (MCE) Product Catalog:

標的別:	ATM/ATR (60) AMPK (1) Amyloid-β (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (15) Autophagy (1) Bacterial (4) Bcl-2 Family (1) BCL6 (1) c-Met/HGFR (1) Caspase (3) CDK (5) Checkpoint Kinase (Chk) (3) CMV (3) DNA-PK (1) DNA/RNA Synthesis (8) Drug Isomer (1) EGFR (1) Endogenous Metabolite (1) HBV (2) Hedgehog (2) Histone Demethylase (1) HSV (4) Interleukin Related (1) Isotope-Labeled Compounds (4) JNK (3) MDM-2/p53 (1) mTOR (4) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (2) p38 MAPK (3) PARP (1) PD-1/PD-L1 (3) PI3K (1) PROTACs (2) Reference Standards (5) Reverse Transcriptase (1) Src (1) STAT (2) STING (4) TLK (1) Topoisomerase (2)
研究分野別:	Cancer (74) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (4)

標的別:

ATM/ATR (60)

AMPK (1)

Amyloid-β (3)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (15)

Autophagy (1)

Bacterial (4)

Bcl-2 Family (1)

BCL6 (1)

c-Met/HGFR (1)

Caspase (3)

CDK (5)

Checkpoint Kinase (Chk) (3)

CMV (3)

DNA-PK (1)

DNA/RNA Synthesis (8)

Drug Isomer (1)

EGFR (1)

Endogenous Metabolite (1)

HBV (2)

Hedgehog (2)

Histone Demethylase (1)

HSV (4)

Interleukin Related (1)

Isotope-Labeled Compounds (4)

JNK (3)

MDM-2/p53 (1)

mTOR (4)

Nucleoside Antimetabolite/Analog (3)

Orthopoxvirus (2)

p38 MAPK (3)

PARP (1)

PD-1/PD-L1 (3)

PI3K (1)

PROTACs (2)

Reference Standards (5)

Reverse Transcriptase (1)

Src (1)

STAT (2)

STING (4)

TLK (1)

Topoisomerase (2)

研究分野別:

Cancer (74)

Cardiovascular Disease (2)

Infection (6)

Inflammation/Immunology (6)

Metabolic Disease (1)

Neurological Disease (4)

阻害剤およびアゴニスト

ペプチド

阻害性抗体

天然物

同位体標識化合物

Targets Recommended: ATM/ATR

製品番号	製品名	Target	研究分野	構造式

HY-19323

Ceralasertib 55+ Cited Publications AZD6738	ATM/ATR	Cancer
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of *ATR* kinase with an IC₅₀ of 1 nM.

HY-13902

Berzosertib 20+ Cited Publications VE-822; VX-970; M6620	ATM/ATR Apoptosis STING Caspase	Infection Metabolic Disease Cancer
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective *ATR* kinase inhibitor. Berzosertib blocks *ATR* kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-B0097

Floxuridine 10+ Cited Publications 5-Fluorouracil 2'-deoxyriboside	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-136270

Gartisertib 5 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective *ATR* inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-101566

Elimusertib 10+ Cited Publications BAY 1895344	ATM/ATR	Cancer
Elimusertib (BAY-1895344) is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .

HY-12016

KU-55933 Maximum Cited Publications 62 Publications Verification	ATM/ATR Autophagy	Cancer
KU-55933 is a potent ATM inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective *ATR* kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-111451

Tuvusertib 1 Publications Verification M1774; ATR inhibitor 1	ATM/ATR	Cancer
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active *ATR* inhibitor extracted from patent WO2015187451A1, compound I-l, with a K_i value below 1 μΜ .

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human *ATR-ATRIP* complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-14731

VE-821 50+ Cited Publications	ATM/ATR	Cancer
VE-821 is a potent ATP-competitive inhibitor of *ATR* with K_i/IC₅₀ of 13 nM/26 nM.

HY-P991272

ATR-107 PF-05230900	Interleukin Related	Inflammation/Immunology
ATR-107 (PF-05230900) is a humanized monoclonal antibody inhibitor that targets the interleukin-21 receptor (IL-21R). The K_a value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .

HY-B0255

Adefovir dipivoxil 2 Publications Verification GS 0840	HBV Orthopoxvirus HSV DNA/RNA Synthesis ATM/ATR CDK	Infection Cancer
Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-171124

Tilatamig samrotecan AZD9592	Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis	Cancer
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .

HY-15520

CGK733 5+ Cited Publications	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-15557

AZ20 5+ Cited Publications	ATM/ATR	Cancer
AZ20 is a potent and selective inhibitor of *ATR* with an IC₅₀ of 5 nM, and has 8-fold selectivity against mTOR (IC₅₀=38 nM).

HY-N7046

Silybin B Silibinin B	Amyloid-β Apoptosis JNK p38 MAPK	Neurological Disease Cancer
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-150617

Lartesertib 1 Publications Verification M4076; ATM inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-161615

PROTAC ATR degrader-2	PROTACs ATM/ATR Apoptosis	Inflammation/Immunology Cancer
PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC₅₀ of 29.6 nM against ATR, and its IC₅₀ values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of *ATR* protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .

HY-15521

ETP-46464 2 Publications Verification	mTOR ATM/ATR	Cancer
ETP-46464 is an effective mTOR and *ATR* inhibitor with IC₅₀s of 0.6 and 14 nM, respectively.

HY-101566A

Elimusertib hydrochloride 10+ Cited Publications BAY 1895344 hydrochloride	ATM/ATR	Cancer
Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective *ATR* inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity . Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas .

HY-159480

AD1058	Src ATM/ATR Apoptosis mTOR AMPK	Cancer
AD1058 is an orally active, selective, and BBB-permeable inhibitor of *ATR* (IC₅₀: 1.6 nM). AD1058 exhibits anticancer activity by inhibiting tumor cell proliferation, inducing cell cycle arrest, and promoting apoptosis. AD1058 is suitable for research on advanced malignancies and brain metastases .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-13816

NU6027	CDK ATM/ATR	Cancer
NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of *ATR* and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .

HY-19323A

(S)-Ceralasertib 2 Publications Verification (S)-AZD6738	ATM/ATR	Cancer
(S)-Ceralasertib ((S)-AZD6738) is the S-enantiomer of Ceralasertib (HY-19323). (S)-Ceralasertib is the inhibitor for ataxia telangiectasia mutated and rad3 related (ATR) .

HY-161138

WK369	BCL6 Apoptosis	Cancer
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .

HY-N6954

Garcinone C 2 Publications Verification	ATM/ATR STAT CDK Hedgehog	Inflammation/Immunology Cancer
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent *ATR* (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (ASELPASQPQPFSAKKK) is a peptide substrate for ATR protein kinase and can be used to detect ATR kinase activity .

HY-B0097R

Floxuridine (Standard) 5-Fluorouracil 2'-deoxyriboside (Standard)	Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (Standard) is the analytical standard of Floxuridine. This product is intended for research and analytical applications. Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-172448

YY2201	ATM/ATR	Cancer
YY2201 is a highly potent and selective *ATR* inhibitor with an IC₅₀ of 8 nM. YY2201 shows >200-fold more selective for ATR than mTOR. YY2201 inhibits tumor progression in broad-spectrum cancer types (such as lung cancer) .

HY-101566S

Elimusertib-d3 BAY 1895344-d₃	ATM/ATR	Cancer
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-171745

ATR-IN-32	ATM/ATR	Cancer
ATR-IN-32 is an orally active *ATR* inhibitor. ATR-IN-32 potently inhibits the proliferation of MIA PaCa-2 cells. ATR-IN-32 exerts significant tumor growth inhibition in mice bearing LOVO and HT-29 xenografts. ATR-IN-32 can be used for the study of cancers mediated by ATR protein kinase, such as colorectal cancer, pancreatic cancer .

HY-147190

ATR-IN-19	ATM/ATR	Cancer
ATR-IN-19 (Compound 15 R-configure) is an *ATR* inhibitor .

HY-174828

ATR/PARP1-IN-1	PARP ATM/ATR Apoptosis	Cancer
ATR/PARP1-IN-1 is a potent *ATR* and PARP1 dual inhibitor with IC₅₀s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .

HY-145450

ATR-IN-9	ATM/ATR	Cancer
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC₅₀ of 10 nM .

HY-149952

ATR-IN-23	ATM/ATR	Cancer
ATR-IN-23 (Compound 34) is a potent and selective *ATR* inhibitor with an IC₅₀ of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .

HY-153462

ATR-IN-24	ATM/ATR	Cancer
ATR-IN-24 (Compound 1) is a *ATR* inhibitor. ATR-IN-24 has anticancer activity .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent *ATR* kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-153729

ATR-IN-29	ATM/ATR	Cancer
ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC₅₀ value of 1 nM. ATR-IN-29 shows antiproliferative activity .

HY-147569

ATR-IN-17	ATM/ATR	Cancer
ATR-IN-17 (compound 88) is a potent *ATR* kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

HY-147568

ATR-IN-16	ATM/ATR	Cancer
ATR-IN-16 (compound 46) is a potent *ATR* kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .

HY-142671

ATR-IN-5	ATM/ATR	Cancer
ATR-IN-5 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .

HY-153393

ATR-IN-21	ATM/ATR	Cancer
ATR-IN-21 (compound 60) is a potent *ATR* inhibitor with an IC₅₀ value of <1000 nM .

HY-142672

ATR-IN-6	ATM/ATR	Cancer
ATR-IN-6 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .

HY-142924

ATR-IN-8	ATM/ATR	Cancer
ATR-IN-8 is a potent inhibitor of *ATR. ATR* is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .

HY-144435

ATR-IN-11	ATM/ATR	Cancer
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

HY-144214

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-161838

ICT10336	ATM/ATR	Cancer
ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit *ATR* activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.

HY-123502

Ceralasertib formate AZD-6738 formate	ATM/ATR	Cancer
Ceralasertib formate is a potent, selective and orally active *ATR* inhibitor with an IC₅₀ value of 1 nM. Ceralasertib formate inhibits cell viability and induces DNA damage. Ceralasertib formate induces cell senescence. Ceralasertib formate shows antitumor activity .

製品番号	製品名	Target	研究分野

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (ASELPASQPQPFSAKKK) is a peptide substrate for ATR protein kinase and can be used to detect ATR kinase activity .

製品番号	製品名	Target	研究分野	Image

HY-P991272

ATR-107 PF-05230900	Interleukin Related	Inflammation/Immunology
ATR-107 (PF-05230900) is a humanized monoclonal antibody inhibitor that targets the interleukin-21 receptor (IL-21R). The K_a value of ATR-107 is 2-4 nM in cynomolgus monkeys, 16 nM in mice, and 71 nM in rats. ATR-107 can be used in research related to systemic lupus erythematosus and air pouch inflammation .

製品番号	製品名	Category	Target	構造式

HY-B0255

Adefovir dipivoxil 2 Publications Verification GS 0840	Infection 天然物 Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	HBV Orthopoxvirus HSV DNA/RNA Synthesis ATM/ATR CDK
Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N7046

Silybin B Silibinin B	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Amyloid-β Apoptosis JNK p38 MAPK
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-N6954

Garcinone C 2 Publications Verification	other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Guttiferae Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	ATM/ATR STAT CDK Hedgehog
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

HY-B0255R

Adefovir dipivoxil (Standard) GS 0840 (Standard)	Structural Classification 天然物 Endogenous metabolite Source Classification	Reference Standards HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite
Adefovir dipivoxil (Standard) is the analytical standard of Adefovir dipivoxil. This product is intended for research and analytical applications. Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N7046R

Silybin B (Standard) Silibinin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Reference Standards JNK Amyloid-β p38 MAPK Apoptosis
Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-N6954R

Garcinone C (Standard)	Structural Classification other families Xanthones Garcinia oblongifolia Champ. ex Benth. Guttiferae Phenols Polyphenols Plants Source Classification	Reference Standards ATM/ATR STAT CDK Hedgehog
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

HY-N15249

4"-Isovalerylspiramycin I Isovalerylspiramycin I; Shengjimycin E	Structural Classification 天然物 Microorganisms Source Classification	Topoisomerase DNA/RNA Synthesis Checkpoint Kinase (Chk) Apoptosis Bacterial
4"-Isovalerylspiramycin I (Isovalerylspiramycin I) is a topoisomerase 1 (TOP1) inhibitor and an antitumor agent. 4"-Isovalerylspiramycin I directly binds to TOP1, suppresses DNA replication, and induces DNA damage. 4"-Isovalerylspiramycin I downregulates phosphorylated CHEK1 and the ATR/CHEK1 DNA damage repair pathway, blocks DNA repair, and augments DNA damage. 4"-Isovalerylspiramycin I suppresses proliferation, migration, and invasion of osteosarcoma cells. 4"-Isovalerylspiramycin I induces apoptosis and cell cycle arrest in osteosarcoma cells. 4"-Isovalerylspiramycin I exerts antibacterial activity against methicillin-resistant Staphylococcus aureus. 4"-Isovalerylspiramycin I can be used for the research of osteosarcoma, upper respiratory bacterial infections, and methicillin-resistant Staphylococcus aureus infection .

製品番号	製品名	構造式

HY-101566S

Elimusertib-d3
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-W766548

Floxuridine-13C,15N2

Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-N7046S

Silybin B-d3

Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-111451S

Tuvusertib-d3
Tuvusertib-d₃ (M1774-d₃) is the deuterium labeled Tuvusertib (HY-111451). Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor with a K_i value below 1 μΜ.

HY-136270S

Gartisertib-d8
Gartisertib-d₈ (VX-803-d₈) is the deuterium labeled Gartisertib (HY-136270). Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: